☆ 4.4 Editorial Material

Methods for a prompt and reliable laboratory diagnosis of Pompe disease: Report from an international consensus meeting

MOLECULAR GENETICS AND METABOLISM (2008)

期刊

MOLECULAR GENETICS AND METABOLISM

卷 93, 期 3, 页码 275-281

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE

DOI: 10.1016/j.ymgme.2007.09.006

关键词

pompe disease; glycogen storage disease type II; acid maltase deficiency; diagnosis; lysosomal acid alpha-glucosidase; enzyme assay; acarbose

类别

Endocrinology & Metabolism Genetics & Heredity Medicine, Research & Experimental

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Clinical Neurology

Characteristics of Patients With Late-Onset Pompe Disease in France

Claire Lefeuvre, Marie De Antonio, Francoise Bouhour, Celine Tard, Emmanuelle Salort-Campana, Emmeline Lagrange, Anthony Behin, Guilhem Sole, Jean-Baptiste Noury, Sabrina Sacconi, Armelle Magot, Aleksandra Nadaj-Pakleza, Arnaud Lacour, Stephane Beltran, Marco Spinazzi, Pascal Cintas, Dimitri Renard, Maud Michaud, Anne-Laure Bedat-Millet, Helene Prigent, Nadjib Taouagh, Azzeddine Arrassi, Dalil Hamroun, Shahram Attarian, Pascal Laforet, Pompe Study Grp

Summary: This study provides an update on the clinical and biological features of patients with late-onset Pompe disease in the French registry. The findings suggest that the disease is now diagnosed earlier and with lower clinical severity. The 6-minute walk test remains an important method for assessing motor performance and walking ability. The French registry provides a comprehensive overview of Pompe disease in the country and can be used to evaluate responses to future treatments.

NEUROLOGY (2023)

添加到收藏夹

Review Pediatrics

Infantile Pompe disease with intrauterine onset: a case report and literature review

Hongmin Xi, Xianghong Li, Lili Ma, Xiangyun Yin, Ping Yang, Lulu Zhang

Summary: Infants with intrauterine-onset Pompe disease usually exhibit early symptoms of heart disease. Prompt enzyme activity determination and genetic testing are helpful in decision making and treatment planning.

ITALIAN JOURNAL OF PEDIATRICS (2022)

添加到收藏夹

Article Biochemical Research Methods

Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease

Qiushi Liang, Joon M. Pijnenburg, Erikjan Rijkers, Arnold G. Vulto, Ans T. van der Ploeg, Niek P. van Til, Eva C. Vlaar, Jeroen A. A. Demmers, W. W. M. Pim Pijnappel

Summary: Pompe disease is a lysosomal storage disorder characterized by glycogen accumulation in skeletal muscle, leading to profound pathology. This study showed that lentiviral gene therapy with LV-IGF2.GAAco can nearly completely correct disease-associated proteomic changes, supporting its future clinical development as a new treatment option for Pompe disease.

JOURNAL OF PROTEOMICS (2024)

添加到收藏夹

Article Biochemistry & Molecular Biology

From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease

Valentina Sanchez-Porras, Johana Maria Guevara-Morales, Olga Yaneth Echeverri-Pena

Summary: Pompe disease is caused by mutations in the GAA gene, leading to the accumulation of lysosomal glycogen in muscular tissue. Autophagic buildup is a major factor affecting skeletal muscle, and understanding the interconnected mechanisms is important for addressing clinical differences in skeletal and cardiac involvement. This study presents a network reconstruction based on a literature review and database analysis, discussing the role of various intermediates in the pathologic cascade and their relationship with mTORC1/AMPK.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Review Clinical Neurology

Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview

David Stevens, Shadi Milani-Nejad, Tahseen Mozaffar

Summary: This review provides a summary of the clinical presentation and current diagnostic strategies for Pompe disease. It also discusses available treatment options and ongoing research. Recent findings include the inclusion of Pompe disease in newborn screening programs and the completion of clinical trials for new forms of enzyme replacement therapy. However, there are still unmet needs in terms of long-term effectiveness and tissue penetration of these treatments. Future developments include gene therapy and glycogen substrate reduction for Pompe disease and other glycogen storage disorders.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2022)

添加到收藏夹

Article Agriculture, Dairy & Animal Science

Novel Mutation in the Feline GAA Gene in a Cat with Glycogen Storage Disease Type II (Pompe Disease)

Tofazzal Md Rakib, Md Shafiqul Islam, Shigeki Tanaka, Akira Yabuki, Shahnaj Pervin, Shinichiro Maki, Abdullah Al Faruq, Martia Rani Tacharina, Osamu Yamato

Summary: This study reports the genetic defects of a cat diagnosed with Pompe disease and identifies a pathogenic mutation in the feline GAA gene. The clinical outcomes and mutation identified in the cat are identical to those observed in human infantile-onset Pompe disease.

ANIMALS (2023)

添加到收藏夹

Article Genetics & Heredity

Phenotypic implications of pathogenic variant types in Pompe disease

Manuel A. Viamonte, Stephanie L. Filipp, Zara Zaidi, Matthew J. Gurka, Barry J. Byrne, Peter B. Kang

Summary: Research on Pompe disease has shown that different types of GAA gene variants are significantly associated with disease subtype, cardiomyopathy, age at diagnosis, and gross motor function. Multiple types of splice site variants beyond the classic one are often linked to milder phenotypes. Enzyme activity levels remain useful for supporting diagnosis when genetic variants are unclear.

JOURNAL OF HUMAN GENETICS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

CRISPR-mediated generation and characterization of a Gaa homozygous c.1935C>A (p.D645E) Pompe disease knock-in mouse model recapitulating human infantile onset-Pompe disease

Shih-hsin Kan, Jeffrey Y. Huang, Jerry Harb, Allisandra Rha, Nancy D. Dalton, Chloe Christensen, Yunghang Chan, Jeremy Davis-Turak, Jonathan Neumann, Raymond Y. Wang

Summary: This study generated a Gaa(em1935C>A) knock-in mouse model and a myoblast cell line carrying the Gaa c.1935C>A mutation using CRISPR-Cas9 technology. The homozygous Gaa(em1935C>A) mice recapitulated multiple characteristics of infantile-onset Pompe disease, making it an ideal model for evaluating innovative therapies for this disease.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Review Medicine, General & Internal

A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease

Alicia Dorneles Dornelles, Ana Paula Pedroso Junges, Tiago Veiga Pereira, Barbara Correa Krug, Candice Beatriz Treter Goncalves, Juan Clinton Llerena Jr, Priya Sunil Kishnani, Haliton Alves de Oliveira Jr, Ida Vanessa Doederlein Schwartz

Summary: This study reviewed the safety and efficacy of recombinant human GAA enzyme replacement therapy (ERT) for late-onset Pompe disease (LOPD). Results indicated improvements in walking ability, quality of life, and ventilation time with GAA ERT, while adverse events were mild.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Experience with the Urinary Tetrasaccharide Metabolite for Pompe Disease in the Diagnostic Laboratory

Jennifer T. Saville, Maria Fuller

Summary: A mass spectrometric assay for urinary glycogen metabolite was developed as a confirmatory test for Pompe disease in diagnostic laboratories. While useful for confirming PD, further investigation is needed to determine its utility as a biomarker for treatment monitoring.

METABOLITES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity

Michelle Eggers, Charles H. Vannoy, Jianyong Huang, Pravinkumar Purushothaman, Jacqueline Brassard, Carlos Fonck, Hui Meng, Mariah J. Prom, Michael W. Lawlor, Justine Cunningham, Chanchal Sadhu, Fulvio Mavilio

Summary: AT845 administration in mice showed efficacy in increasing GAA activity, clearing glycogen, and improving function, but in cynomolgus macaques high doses caused immune response, inflammation, and cardiac abnormalities. Expression of macaque GAA did not cause toxicity, indicating that the observed effects with AT845 were due to an anti-GAA xenogeneic immune response.

EMBO MOLECULAR MEDICINE (2022)

添加到收藏夹

Review Clinical Neurology

Skeletal muscle magnetic resonance imaging in Pompe disease

Jordi Diaz-Manera, Glenn Walter, Volker Straub

Summary: Pompe disease is characterized by a deficiency of acid alpha-glucosidase leading to muscle weakness and disability. MRI studies on late-onset Pompe disease patients have shown promising results in monitoring disease progression, while studies on infantile-onset Pompe disease patients have shown less consistent changes. More sophisticated MRI sequences, such as diffusion tensor imaging, have also been used in Pompe patients with promising results.

MUSCLE & NERVE (2021)

添加到收藏夹

Article Biology

Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease

Jason Wang, Chris J. Zhou, Alastair Khodabukus, Sabrina Tran, Sang-Oh Han, Aaron L. Carlson, Lauran Madden, Priya S. Kishnani, Dwight D. Koeberl, Nenad Bursac

Summary: The study developed a 3D in vitro model of human skeletal muscle that recapitulates the pathophysiology of Pompe disease. They identified a Pompe disease-specific transcriptional signature and observed a partial reversal of the signature upon in vitro treatment of myobundles with rhGAA.

COMMUNICATIONS BIOLOGY (2021)

添加到收藏夹

Article Genetics & Heredity

Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants

Mei-Yan Chan, Julaina Abdul Jalil, Yusnita Yakob, Siti Aishah Abdul Wahab, Ernie Zuraida Ali, Mohd Khairul Nizam Mohd Khalid, Huey-Yin Leong, Hui-Bein Chew, Jeya Bawani Sivabalakrishnan, Lock-Hock Ngu

Summary: This study describes the clinical and molecular spectrum of Malaysian infantile-onset Pompe disease patients and analyzes their long-term treatment outcomes. The most common mutation identified is c.1935C > A p.(D645E). The results underscore the importance of early diagnosis and treatment in achieving better treatment outcomes.

ORPHANET JOURNAL OF RARE DISEASES (2023)

添加到收藏夹

Article Clinical Neurology

Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease)

Huiting Zhang, Jun Chen, Yuchang Zhu, Xiaotang Ma, Wangtao Zhong

Summary: This study reported a 22-year-old Chinese woman with a diagnosis of adult late-onset Pompe disease. The patient presented with inability to withstand heavy physical activity since childhood, respiratory and ambulation weakness. Mutational analysis of GAA and muscle biopsy were crucial in confirming the diagnosis.

FRONTIERS IN NEUROLOGY (2022)

添加到收藏夹

Review Immunology

Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis

Samar A. Zailaie, Jumana Jamal Siddiqui, Rawan Mansour Al Saadi, Dalia Mohammad Anbari, Amani S. Alomari, Edward James Cupler

Summary: The systematic review and meta-analysis identified 19 serum miRNAs differentially expressed in multiple sclerosis patients, with 8 downregulated, 11 upregulated, and 1 discordant. The pooled AUC was 72% for overall MS patients and PPMS, indicating high sensitivity and specificity. A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing MS from control groups.

IMMUNOLOGICAL INVESTIGATIONS (2022)

添加到收藏夹

Article Medicine, General & Internal

Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases

Agnieszka Lugowska, Galina Baydakova, Alex Ilyushkina, Ekaterina Zakharova, Hanna Mierzewska, Krystyna Szymanska, Jolanta Wierzba, Jolanta Kubalska, Alla Graban, Tomasz Kmiec, Barbara Perkowska-Sumila, Anna Tylki-Szymanska, Malgorzata Bednarska-Makaruk

Summary: Elevated DPP-IV activity was found in patients with various LSDs, with the most significant increases seen in specific types of mucolipidosis, alpha-mannosidosis, and mucopolysaccharidoses. DPP-IV may serve as a valuable diagnostic tool and subject for further study in the understanding of LSDs.

DIAGNOSTICS (2021)

添加到收藏夹

Article Neurosciences

Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia

Norah Alharbi, Rawan Matar, Edward Cupler, Hindi Al-Hindi, Hatem Murad, Iftteah Alhomud, Dorota Monies, Ali Alshehri, Mossaed Alyahya, Brian Meyer, Saeed Bohlega

Summary: This study characterized the profile of dysferlinopathy in 33 Saudi Arabian families, finding a prevalence of 29.46%. The most common phenotypes were Miyoshi myopathy and LGMDR2. The findings were consistent with previous reports from different ethnic groups, and a founder mutation was identified.

FRONTIERS IN NEUROSCIENCE (2022)

添加到收藏夹

Article Biology

Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy

Agnieszka Lugowska, Joanna K. Purzycka-Olewiecka, Rafal Ploski, Grazyna Truszkowska, Maciej Pronicki, Paulina Felczak, Mateusz Spiewak, Aleksandra Podlecka-Pietowska, Martyna Sitek, Zofia T. Bilinska, Przemyslaw Leszek, Malgorzata Bednarska-Makaruk

Summary: We report a case of a 36-year-old man with cerebellar-extrapyramidal syndrome and severe heart failure due to dilated cardiomyopathy of unknown origin. The patient exhibited clinical symptoms of benign forms of ceroid lipofuscinosis type 2 (CLN2) and autosomal recessive spinocerebellar ataxia type 7 (SCAR7), both caused by mutations in the TPP1 gene.

LIFE-BASEL (2022)

添加到收藏夹

Article Virology

SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors

Ashraf Dada, Khalid Elhassan, Rayan Mohammed Bawayan, Ghadeer Albishi, Lama Hefni, Sawsan Bassi, Turki Sobahy, Edward Cupler, Nabeela AlBaz, Ghassan Wali, Basem Alraddadi, Abeer N. Alshukairi

Summary: The study found a high rate of HLA antibody formation in convalescent plasma donors who have recovered from COVID-19. Implementing HLA diagnostic strategies before the administration of convalescent plasma may potentially reduce the risk of transfusion-related acute lung injury (TRALI) in COVID-19 patients.

INTERVIROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Pattern reversal visual evoked potentials (prVEPs) in autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSPTCC) patients with SPG 11 mutations in Saudi Arabia, cross section hospital base study

Nouf Alfaidia, Turki Sobahyb, Qurban Alia, Youssef Al Saida, Gulzar Karima, Haji Khana, Khalil Kurdic, Edward Cuplera

Summary: This retrospective study reported abnormal prVEPs in 81.82% of patients with SPG11 ARHSP-TCC, indicating significantly prolonged P100 bilaterally.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Review Clinical Neurology

A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting

Ali Al Shehri, Abdullah Al-Asmi, Abdullah Mohammed Al Salti, Abubaker Almadani, Ali Hassan, Ahmed K. Bamaga, Edward J. Cupler, Jasem Al-Hashel, Majed M. Alabdali, Mohammed H. Alanazy, Suzan Noori

Summary: Pompe disease is a rare metabolic disorder that requires early diagnosis for effective clinical management. In order to address the challenges faced by clinicians in diagnosing the disease, a group of experts from the Arabian Peninsula region developed a uniform diagnostic algorithm during two committee meetings. This algorithm will aid clinicians in making accurate differential diagnoses for pediatric and adult Pompe disease.

JOURNAL OF NEUROMUSCULAR DISEASES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mucopolysaccharidosis-Plus Syndrome: Report on a Polish Patient with a Novel VPS33A Variant with Comparison with Other Described Patients

Patryk Lipinski, Krzysztof Szczaluba, Piotr Buda, Ekaterina Y. Zakharova, Galina Baydakova, Agnieszka Lugowska, Agnieszka Rozdzynska-Swiatkowska, Zuzanna Cyske, Grzegorz Wegrzyn, Agnieszka Pollak, Rafal Ploski, Anna Tylki-Szymanska

Summary: This article reports a Polish MPS-PS patient with a novel VPS33A gene variant and new clinical features. Functional analysis revealed some related biomarkers, and comparison with other cases helped broaden understanding of the disease phenotype.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Review Clinical Neurology

Saudi consensus recommendations on the management of Neuromyelitis Optica Spectrum Disorders (NMOSD)

Eslam Shosha, Salman A. Aljarallah, Norah Al Fugham, Ahmed H. Al-Jedai, Majed M. Al Luqmani, Yaser M. Al Malik, Hajer Y. Al Mudaiheem, Hessa S. Al Otaibi, Faisal Y. Al Thekair, Ibtisam A. Al Thubaiti, Rumaiza H. Al Yafeai, Nabila S. Ben Slimane, Reem F. Bunyan, Edward J. Cupler, Sultan M. Mubarki, Jameelah A. Saeedi, Mohammad A. Al Jumah

Summary: This article discusses the diagnosis and management of NMOSD. NMOSD is an autoimmune disease characterized by inflammation of the optic nerve and/or spinal cord, leading to varying degrees of movement impairment or paralysis. The newly approved diagnostic criteria improve the accuracy of NMOSD diagnosis. The management of NMOSD is undergoing significant changes due to the emergence of new therapeutic options.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

Fawzi Babtain, Abdulaziz Bajafar, Ohoud Nazmi, Manal Badawi, Ahmed Basndwah, Areej Bushnag, Edward Cupler, Ahmed Hassan

Summary: The impact of the COVID-19 pandemic on multiple sclerosis (MS) remains unclear. This retrospective study found a decrease in MS disease activities during the pandemic, possibly due to underreporting. COVID-19 infection in MS patients showed a benign disease course, with no association with clinical relapses or MRI changes.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Review Clinical Neurology

Saudi consensus recommendations on the management of multiple sclerosis: MS management in children and adolescents

Reem F. Bunyan, Abdulaziz M. AlAbdulSalam, Rayan G. Albarakati, Awad A. Al Harbi, Dema A. Alissa, Ahmed H. Al-Jedai, Nuha M. AlKhawajah, Yaser M. Al Malik, Mousa A. Almejally, Hajer Y. Al-Mudaiheem, Hind A. AlNajashi, Amani A. AlShehri, Ibtisam A. Althubaiti, Rumaiza H. AlYafeai, Mohammed A. Babakkor, Edward J. Cupler, Mamdouh H. Ka, Jameelah A. Saeedi, Eslam Shosha, Mohammed A. Al Jumah

Summary: This article provides an overview of the key recommendations for the diagnosis and management of multiple sclerosis and other CNS inflammatory demyelinating disorders in pediatric and adolescent patients in Saudi Arabia. Careful differential diagnosis is crucial in young patients to exclude alternative diagnoses such as ADEM or NMOSD.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Deterioration of visual quality and acuity as the first sign of ceroid lipofuscinosis type 3 (CLN3), a rare neurometabolic disease

Joanna Karolina Purzycka-Olewiecka, Katarzyna Hetmanczyk-Sawicka, Tomasz Kmiec, Dominika Szczesniak, Joanna Trubicka, Maciej Krawczynski, Maciej Pronicki, Agnieszka Lugowska

Summary: Ceroid lipofuscinosis type 3 (CLN3) is a neurodegenerative metabolic disease characterized by progressive visual loss, epilepsy, and dementia. Lipofuscin deposits and vacuolized lymphocytes are indicative of CLN3 diagnosis. The most common cause of CLN3 is a large deletion of 1.02 kb in exons 7 and 8 of the CLN3 gene. This study reports 4 patients from 2 families who experienced visual deterioration as the initial clinical sign, followed by neurological symptoms. All patients had the 1.02 kb deletion in the CLN3 gene detected. The presence of abnormal structures and the economic feasibility of the 1.02 kb deletion test support its use in diagnosing CLN3.

METABOLIC BRAIN DISEASE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach

Paulina Szymanska-Rozek, Barbara Czartoryska, Grazina Kleinotiene, Patryk Lipinski, Anna Tylki-Szymanska, Agnieszka Lugowska

Summary: Chitotriosidase is an enzyme produced by activated macrophages, especially in Gaucher disease, where macrophages loaded with phagocytozed glycosphingolipid secrete chitotriosidase in proportion to the degree of overload. Gaucher disease is caused by the deficiency of beta-glucocerebrosidase activity and results in the storage of glucosylceramide in tissue macrophages. Chitotriosidase has been found to be a sensitive biomarker for enzyme replacement therapy in GD patients.

BIOMOLECULES (2023)

添加到收藏夹

Meeting Abstract Immunology

SARS-COV-2 VIRUS INDUCES ANTI-HLA ANTIBODY FORMATION IN CONVALESCENT PLASMA DONORS

A. Dada, R. Bawayan, D. Bayumi, G. Albishi, K. Elfaki, S. Bassi, E. Cupler, T. Sobahy, W. Ghassan, A. Alshukairi

HUMAN IMMUNOLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review

Raed Alroughani, Jihad Inshasi, Mona Al Khawajah, Samar Farouk Ahmed, Yaser Al Malik, Jaber Alkhabouri, Ahmed Shatila, Salman Aljarallah, Edward J. Cupler, Shireen Al Qureshi, Mona Thakre, Heba Elhasin, Aly Ezzat, Sherif Roushdy

Summary: This study provides real-world evidence for the usage of teriflunomide in the management of multiple sclerosis in GCC countries. Expert recommendations are given for patient profiles and considerations such as cost-effectiveness, patient preference, adherence, monitoring, established safety profile, and COVID-19 status.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.